Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’
Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’
View filing at SEC.gov →20 most recent filings and news items mentioning JNJ. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/JNJ/news?limit=20"
Pull JNJ filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayJim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’
View filing at SEC.gov →Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
View filing at SEC.gov →Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287
View filing at SEC.gov →Johnson & Johnson announced Executive Vice President Jennifer Taubert will retire on September 1 after 21 years leading the $60B Innovative Medicine unit. Tom Cavanaugh is appointed to succeed her as EVP, Worldwide Chairman of the business.
View filing at SEC.gov →Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $282
View filing at SEC.gov →Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
View filing at SEC.gov →Johnson & Johnson Says FDA Grants Priority Review To Subcutaneous Amivantamab For Recurrent Or Metastatic Head And Neck Cancer, Citing 42% Overall Response Rate In OrigAMI-4 Study
View filing at SEC.gov →Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
View filing at SEC.gov →Johnson & Johnson Says 2026 Adj Operational EPS And Adj EPS Expected To Decrease By $0.64; 2027 Adj Operational EPS And Adj EPS Expected To Decrease By $1.36
View filing at SEC.gov →Johnson & Johnson Partners With Sail Biomedicines On In Vivo CAR-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027
View filing at SEC.gov →Reported Earlier, Johnson & Johnson Proposes $5.5B Resolution Of Roughly 76,000 Ovarian Talc Claims, With First Payment Of Up To $3B In 2027, Conditioned On 95% Plaintiff Participation
View filing at SEC.gov →Johnson & Johnson Reaches $5.5B Comprehensive Ovarian Talc Litigation Agreement Based On Participation Of At Least 95% Of Remaining Claims
View filing at SEC.gov →Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest
View filing at SEC.gov →After a favorable court ruling on specific causation, Johnson & Johnson is proposing a resolution to roughly 76,000 ovarian talc claims conditioned on 95% participation, an efficient outcome that eliminates future litigation expenses.
View filing at SEC.gov →Johnson & Johnson Announces Topline Results From Phase 3 MonumenTAL-6 Study Evaluating TECVAYLI + TALVEY In Adult Patients With Multiple Myeloma; Study Demonstrated Statistically Significant And Clinically Meaningful Improvements In Progression-Free Survival And Overall Survival
View filing at SEC.gov →Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
View filing at SEC.gov →Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US
View filing at SEC.gov →Johnson & Johnson Receives FDA De Novo Authorization For Its OTTAVA Robotic Surgical System
View filing at SEC.gov →FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
View filing at SEC.gov →Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target
View filing at SEC.gov →